Grachev, Igor D.
Meyer, Philipp M.
Becker, Georg A.
Bronzel, Marcus
Marsteller, Doug
Pastino, Gina
Voges, Ole
Rabinovich, Laura
Knebel, Helena
Zientek, Franziska
Rullmann, Michael
Sattler, Bernhard
Patt, Marianne
Gerhards, Thilo
Strauss, Maria
Kluge, Andreas
Brust, Peter
Savola, Juha-Matti
Gordon, Mark F.
Geva, Michal
Hesse, Swen
Barthel, Henryk
Hayden, Michael R.
Sabri, Osama
Funding for this research was provided by:
This PET investigation was funded by Teva Pharmaceuticals USA.
Article History
Received: 3 June 2020
Accepted: 7 September 2020
First Online: 29 September 2020
Compliance with ethical standards
:
: Dr. Grachev was an employee of Teva Pharmaceuticals at the time of the study and is currently an employee of Guide Pharmaceutical Consulting. Drs. Gordon, Rabinovich, and Knebel are working for Teva Pharmaceuticals. Drs. Savola, Marsteller, and Pastino were employed by Teva Pharmaceuticals at the time of the study. Drs. Kluge, Bronzel, and Voges are staff members of ABX-CRO Advanced Pharmaceutical Services. Drs. Geva and Hayden who are now employed by Prilenia Therapeutics Development were former staff members of Teva Pharmaceuticals at the time of the study. In September 2018, Teva Pharmaceutical sold and transferred its rights pertaining to pridopidine to Prilenia Therapeutics. The remaining authors declare no competing interests.
: This study was approved by the local ethics committee, the Federal Institute for Drugs and Medical Devices and the German Federal Office for Radiation Protection, and was performed according to the World Medical Association Declaration of Helsinki 1964 and its later amendments or comparable ethical standards (Clinical ExternalRef removed Identifier: NCT03019289; EUDRA-CT-Nr. 2016-001757-41). The PET study performed at the Department of Nuclear Medicine, University Hospital of Leipzig, Germany.
: All study participants gave written informed consent.